ophthalmology
-
Roche’s bispecific antibody therapy sets a new record as the “king of drugs” in ophthalmology
DrugTimes Team will follow up on this subject. Please stay tuned
-
After ten years, Merck returns to the field of ophthalmology with a $3 billion investment!
Congratulations to Merck and EyeBio!
